Selective inhibitors of cardiac ADPR cyclase as novel anti-arrhythmic compounds

@inproceedings{Kannt2012SelectiveIO,
  title={Selective inhibitors of cardiac ADPR cyclase as novel anti-arrhythmic compounds},
  author={Aimo Kannt and Kerstin Sicka and Katja Kroll and Dieter Kadereit and Heinz Goegelein},
  booktitle={Naunyn-Schmiedeberg's Archives of Pharmacology},
  year={2012}
}
ADP-ribosyl cyclases (ADPRCs) catalyse the conversion of nicotinamide adenine dinucleotide to cyclic adenosine diphosphoribose (cADPR) which is a second messenger involved in Ca2+ mobilisation from intracellular stores. Via its interaction with the ryanodine receptor Ca2+ channel in the heart, cADPR may exert arrhythmogenic activity. To test this hypothesis, we have studied the effect of novel cardiac ADPRC inhibitors in vitro and in vivo in models of ventricular arrhythmias. Using a high… CONTINUE READING